RU2010117178A - Опосредованная самокомплементарными aav доставка молекул, интерферирующих рнк для лечения или профилактики глазных заболеваний - Google Patents
Опосредованная самокомплементарными aav доставка молекул, интерферирующих рнк для лечения или профилактики глазных заболеваний Download PDFInfo
- Publication number
- RU2010117178A RU2010117178A RU2010117178/15A RU2010117178A RU2010117178A RU 2010117178 A RU2010117178 A RU 2010117178A RU 2010117178/15 A RU2010117178/15 A RU 2010117178/15A RU 2010117178 A RU2010117178 A RU 2010117178A RU 2010117178 A RU2010117178 A RU 2010117178A
- Authority
- RU
- Russia
- Prior art keywords
- eye
- scaav
- interfering rna
- vector
- rna molecule
- Prior art date
Links
- 230000002452 interceptive effect Effects 0.000 title claims abstract 13
- 208000030533 eye disease Diseases 0.000 title claims abstract 6
- 230000002265 prevention Effects 0.000 title 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims abstract 12
- 238000000034 method Methods 0.000 claims abstract 12
- 108020004459 Small interfering RNA Proteins 0.000 claims abstract 8
- 108020004999 messenger RNA Proteins 0.000 claims abstract 6
- 239000000203 mixture Substances 0.000 claims abstract 6
- 239000013609 scAAV vector Substances 0.000 claims abstract 6
- 239000013598 vector Substances 0.000 claims abstract 6
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims abstract 4
- 206010013774 Dry eye Diseases 0.000 claims abstract 4
- 206010030043 Ocular hypertension Diseases 0.000 claims abstract 4
- 230000033115 angiogenesis Effects 0.000 claims abstract 4
- 230000004968 inflammatory condition Effects 0.000 claims abstract 4
- 210000002845 virion Anatomy 0.000 claims abstract 4
- 230000003612 virological effect Effects 0.000 claims abstract 4
- 208000010412 Glaucoma Diseases 0.000 claims abstract 3
- 208000022873 Ocular disease Diseases 0.000 claims abstract 3
- 238000002347 injection Methods 0.000 claims abstract 2
- 239000007924 injection Substances 0.000 claims abstract 2
- 238000010255 intramuscular injection Methods 0.000 claims abstract 2
- 239000007927 intramuscular injection Substances 0.000 claims abstract 2
- 239000007928 intraperitoneal injection Substances 0.000 claims abstract 2
- 238000010253 intravenous injection Methods 0.000 claims abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- 108090000623 proteins and genes Proteins 0.000 claims abstract 2
- 238000011200 topical administration Methods 0.000 claims abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97655207P | 2007-10-01 | 2007-10-01 | |
| US60/976,552 | 2007-10-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2010117178A true RU2010117178A (ru) | 2011-11-10 |
Family
ID=40042637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010117178/15A RU2010117178A (ru) | 2007-10-01 | 2008-10-01 | Опосредованная самокомплементарными aav доставка молекул, интерферирующих рнк для лечения или профилактики глазных заболеваний |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20090087413A1 (enExample) |
| EP (1) | EP2192926A1 (enExample) |
| JP (1) | JP2010540564A (enExample) |
| KR (1) | KR20100061792A (enExample) |
| CN (1) | CN101815536A (enExample) |
| AU (1) | AU2008308784B2 (enExample) |
| BR (1) | BRPI0817937A2 (enExample) |
| CA (1) | CA2694091A1 (enExample) |
| MX (1) | MX2010001608A (enExample) |
| RU (1) | RU2010117178A (enExample) |
| WO (1) | WO2009046059A1 (enExample) |
| ZA (1) | ZA201000423B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2019143A1 (en) | 2007-07-23 | 2009-01-28 | Genethon | CNS gene delivery using peripheral administration of AAV vectors |
| EP2058401A1 (en) | 2007-10-05 | 2009-05-13 | Genethon | Widespread gene delivery to motor neurons using peripheral injection of AAV vectors |
| EP2287323A1 (en) * | 2009-07-31 | 2011-02-23 | Association Institut de Myologie | Widespread gene delivery to the retina using systemic administration of AAV vectors |
| EA202091105A1 (ru) * | 2010-04-23 | 2020-12-30 | Юниверсити Оф Флорида Рисерч Фаундейшн, Инк. | Композиции гуанилатциклазы и способы лечения врожденного амавроза лебера типа 1 (lca1) |
| CN103505743A (zh) * | 2012-06-21 | 2014-01-15 | 北京命码生科科技有限公司 | 含功能性microRNA/siRNA的细胞微粒子及其应用 |
| EP4012035B1 (en) * | 2014-09-16 | 2024-11-06 | Genzyme Corporation | Adeno-associated viral vectors for treating myocilin (myoc) glaucoma |
| KR102612871B1 (ko) | 2014-09-16 | 2023-12-13 | 젠자임 코포레이션 | 마이오실린(myoc) 녹내장을 치료하기 위한 아데노-관련 바이러스 벡터 |
| CA2961523A1 (en) * | 2014-09-16 | 2016-03-24 | Genzyme Corporation | Adeno-associated viral vectors for treating myocilin (myoc) glaucoma |
| GB201809588D0 (en) * | 2018-06-12 | 2018-07-25 | Univ Bristol | Materials and methods for modulating intraocular and intracranial pressure |
| US20220403438A1 (en) | 2019-10-08 | 2022-12-22 | Trustees Of Boston College | Proteins containing multiple, different unnatural amino acids and methods of making and using such proteins |
| MX2022010936A (es) | 2020-03-05 | 2022-11-16 | Neotx Therapeutics Ltd | ³métodos y composiciones para el tratamiento del cáncer con células inmunológicas. |
| EP4161583A1 (en) * | 2020-06-05 | 2023-04-12 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods and pharmaceutical compositions for treating ocular diseases |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2256265T3 (es) * | 2000-06-01 | 2006-07-16 | University Of North Carolina At Chapel Hill | Vectores de parvovirus duplicados. |
| US20040209832A1 (en) * | 2001-11-30 | 2004-10-21 | Mcswiggen James | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| US20040198682A1 (en) * | 2001-11-30 | 2004-10-07 | Mcswiggen James | RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (siNA) |
| US20050048529A1 (en) * | 2002-02-20 | 2005-03-03 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA) |
| WO2005019422A2 (en) * | 2003-08-13 | 2005-03-03 | The Board Of Trustees Of The University Of Illinois | Silencing of tgf-beta receptor type ii expression by sirna |
| US7947267B2 (en) * | 2004-10-08 | 2011-05-24 | Potentia Pharmaceuticals, Inc. | Viral complement control proteins for eye disorders |
| TWI386225B (zh) * | 2004-12-23 | 2013-02-21 | Alcon Inc | 用於治療眼睛病症的結締組織生長因子（ＣＴＧＦ）ＲＮＡ干擾（ＲＮＡｉ）抑制技術 |
| TWI401316B (zh) * | 2004-12-23 | 2013-07-11 | Alcon Inc | 用於治療青光眼之血清澱粉樣蛋白Ａ的ＲＮＡｉ抑制作用 |
| TW200639253A (en) * | 2005-02-01 | 2006-11-16 | Alcon Inc | RNAi-mediated inhibition of ocular targets |
| BRPI0609206A2 (pt) * | 2005-03-11 | 2010-03-02 | Alcon Inc | inibiÇço mediada por rnai de proteÍna relacionada frizzled-1 para tratamento de glaucoma |
| GB0521351D0 (en) * | 2005-10-20 | 2005-11-30 | Genomica Sau | Modulation of TRPV expression levels |
| AR057252A1 (es) * | 2005-12-27 | 2007-11-21 | Alcon Mfg Ltd | Inhibicion de rho quinasa mediada por arni para el tratamiento de trastornos oculares |
| TW200731980A (en) * | 2005-12-29 | 2007-09-01 | Alcon Mfg Ltd | RNAi-mediated inhibition of HIF1A for treatment of ocular angiogenesis |
| TW200808360A (en) * | 2006-04-13 | 2008-02-16 | Alcon Mfg Ltd | RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions |
| US8298818B2 (en) * | 2006-04-28 | 2012-10-30 | University Of Florida Research Foundation, Inc. | Self-complementary adeno-associated virus having a truncated CMV-chicken β-actin promoter |
| AU2007253776B2 (en) * | 2006-05-19 | 2012-04-26 | Arrowhead Research Corporation | RNAi-mediated inhibition of tumor necrosis factor alpha-related conditions |
| BRPI0715821A2 (pt) * | 2006-08-24 | 2013-07-23 | Alcon Res Ltd | inibiÇço de gremlina mediada por rnai para tratamento de condiÇÕes relacionadas À iop |
| EP2137205A2 (en) * | 2007-02-26 | 2009-12-30 | Quark Pharmaceuticals, Inc. | Inhibitors of rtp801 and their use in disease treatment |
| US7973019B1 (en) * | 2007-10-03 | 2011-07-05 | Alcon Research, Ltd. | Transferrin/transferrin receptor-mediated siRNA delivery |
| TW200932274A (en) * | 2007-12-18 | 2009-08-01 | Alcon Res Ltd | Interfering RNA delivery system and uses thereof |
-
2008
- 2008-10-01 WO PCT/US2008/078380 patent/WO2009046059A1/en not_active Ceased
- 2008-10-01 CN CN200880110028A patent/CN101815536A/zh active Pending
- 2008-10-01 KR KR1020107003620A patent/KR20100061792A/ko not_active Withdrawn
- 2008-10-01 EP EP08835867A patent/EP2192926A1/en not_active Withdrawn
- 2008-10-01 RU RU2010117178/15A patent/RU2010117178A/ru not_active Application Discontinuation
- 2008-10-01 BR BRPI0817937 patent/BRPI0817937A2/pt not_active IP Right Cessation
- 2008-10-01 CA CA2694091A patent/CA2694091A1/en not_active Abandoned
- 2008-10-01 JP JP2010527251A patent/JP2010540564A/ja active Pending
- 2008-10-01 MX MX2010001608A patent/MX2010001608A/es not_active Application Discontinuation
- 2008-10-01 AU AU2008308784A patent/AU2008308784B2/en not_active Ceased
- 2008-10-01 US US12/243,100 patent/US20090087413A1/en not_active Abandoned
-
2010
- 2010-01-20 ZA ZA2010/00423A patent/ZA201000423B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2694091A1 (en) | 2009-04-09 |
| AU2008308784B2 (en) | 2013-07-18 |
| ZA201000423B (en) | 2011-03-30 |
| JP2010540564A (ja) | 2010-12-24 |
| BRPI0817937A2 (pt) | 2015-04-07 |
| MX2010001608A (es) | 2010-03-15 |
| US20090087413A1 (en) | 2009-04-02 |
| WO2009046059A1 (en) | 2009-04-09 |
| KR20100061792A (ko) | 2010-06-09 |
| AU2008308784A1 (en) | 2009-04-09 |
| CN101815536A (zh) | 2010-08-25 |
| EP2192926A1 (en) | 2010-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2010117178A (ru) | Опосредованная самокомплементарными aav доставка молекул, интерферирующих рнк для лечения или профилактики глазных заболеваний | |
| JP2010540564A5 (enExample) | ||
| Casson | Medical therapy for glaucoma: A review | |
| Guzman‐Aranguez et al. | Small‐interfering RNA s (siRNA s) as a promising tool for ocular therapy | |
| JP2010501188A5 (enExample) | ||
| JP2023099171A (ja) | 緑内障を治療するためのＷｎｔ５ａの調節 | |
| CN102164600A (zh) | 用于治疗眼的新血管发生病症的包含索拉菲尼的眼科药物组合物 | |
| Li et al. | A new approach of delivering siRNA to the cornea and its application for inhibiting herpes simplex keratitis | |
| WO2015187840A2 (en) | Methods and formulations for treatment of ocular disorders | |
| Tan et al. | Effects of lentivirus-mediated C3 expression on trabecular meshwork cells and intraocular pressure | |
| Yu et al. | Clinical evaluation of intravitreal injection of ganciclovir in refractory corneal endotheliitis | |
| ATE491715T1 (de) | Oligoribonukleotide und verfahren zu deren anwendung bei der behandlung von fibrotischen leiden und anderen krankheiten | |
| Hnik et al. | Antisense oligonucleotide therapy in diabetic retinopathy | |
| RU2014151992A (ru) | Лечение воспалительных заболеваний глаз с применением лахинимода | |
| Roddy et al. | Transgene expression of Stanniocalcin-1 provides sustained intraocular pressure reduction by increasing outflow facility | |
| RU2008120702A (ru) | Модулирование экспрессии 11бета-гидроксистероидной дегидрогеназы 1 для лечения глазных болезней | |
| Xie et al. | MLN4924 inhibits hedgehog signaling pathway and activates autophagy to alleviate mouse laser-induced choroidal neovascularization lesion | |
| Yuan et al. | Lentivirus-mediated RNA interference of vascular endothelial growth factor in monkey eyes with iris neovascularization | |
| RU2463045C1 (ru) | Способ лечения цереброваскулярных заболеваний и астенического синдрома | |
| RU2015112131A (ru) | КиРНК И ИХ ИСПОЛЬЗОВАНИЕ В СПОСОБАХ И КОМПОЗИЦИЯХ ДЛЯ ЛЕЧЕНИЯ И/ИЛИ ПРОФИЛАКТИКИ ГЛАЗНЫХ ЗАБОЛЕВАНИЙ | |
| EP2776565A1 (en) | Methods and compositions for treating diseases, disorders or injury of the nervous system | |
| RU2343885C1 (ru) | Способ лечения субэпителиального флера роговицы после фоторефракционной кератэктомии | |
| JPWO2020180865A5 (enExample) | ||
| Martínez et al. | Preclinical development of RNAi-inducing oligonucleotide therapeutics for eye diseases | |
| KR20240016895A (ko) | 카텝신 s 발현억제를 통한 황반변성의 예방 및 치료 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20130621 |